Recent Quotes
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TransCode Therapeutics, Inc. - Common Stock (NQ:RNAZ)

1.840 -0.050 (-2.65%)
Streaming Delayed Price Updated: 11:31 AM EDT, Sep 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,755
Open 1.860
Bid (Size) 1.830 (1,200)
Ask (Size) 1.910 (100)
Prev. Close 1.890
Today's Range 1.832 - 1.950
52wk Range 1.832 - 20.99
Shares Outstanding 833,683
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer
From RedChip Companies, Inc. (Media Suite)
Via ACCESS Newswire
BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Reports TTX-MC138 Survival Benefit in Preclinical Breast Cancer Bone Metastasis Study
Via Investor Brand Network

Performance

YTD
-75.1%
-75.1%
1 Month
-52.6%
-52.6%
3 Month
-63.1%
-63.1%
6 Month
-81.0%
-81.0%
1 Year
-83.1%
-83.1%

More News

Read More
News headline image
Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
From RedChip Companies, Inc. (Media Suite)
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) to Host First R&D Webcast Highlighting Phase 2a Oncology Program
Via Investor Brand Network
BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Reports Positive Phase 1a Results for TTX-MC138 and Advances Program Toward Phase 2a
Via Investor Brand Network
BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Initiates Phase 2a Trial of TTX-MC138 in Colorectal Cancer Patients with Minimal Residual Disease
Via Investor Brand Network
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints Scientific Advisory Board Chair, Signs Research Agreement With Michigan State University
Via Investor Brand Network
MissionIRNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Secures Up to $20 Million Financing Agreement
Via Investor Brand Network
BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Secures Exclusive Global License to Three Unleash Immuno-Oncolytics Drug Candidates
Via Investor Brand Network
BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Announces Publication On Tumor-Selective RIG-I Immunotherapy Approach
Via Investor Brand Network
BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Submits IND Amendment for Planned Phase 2a Trial of TTX-MC138 in Colorectal Cancer
Via Investor Brand Network
BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Publishes Preclinical Data Supporting TTX-MC138 for Glioblastoma
Via Investor Brand Network
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints Jack E. Stover to Board of Directors
Via Investor Brand Network
News headline image
The market is filled with gapping stocks in Thursday's session. ↗
Via Chartmill
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Launch Collaboration to Evaluate TTX-MC138 in PRE-I-SPY Trial
Via Investor Brand Network
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints Dr. Michel Janicot as Senior Development Officer
Via Investor Brand Network
BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Completes Phase 1a Trial of TTX-MC138, Advancing to Phase 2 Evaluation
Via Investor Brand Network
News headline image
MAGA Stocks Undercard: MYSE, XBIO, ATON, ACXP, RDZN – Innovators Driving Next Tech, Blockchain, AI Wave – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Acquires Polynoma, Secures $25 Million Investment from CK Life Sciences to Advance Phase 2 Trial of TTX-MC138
Via Investor Brand Network
News headline image
TransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout ↗
Via Benzinga
News headline image
TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset ↗
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Why FedEx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga

Frequently Asked Questions

Is TransCode Therapeutics, Inc. - Common Stock publicly traded?
Yes, TransCode Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does TransCode Therapeutics, Inc. - Common Stock trade on?
TransCode Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for TransCode Therapeutics, Inc. - Common Stock?
The ticker symbol for TransCode Therapeutics, Inc. - Common Stock is RNAZ on the Nasdaq Stock Market
What is the current price of TransCode Therapeutics, Inc. - Common Stock?
The current price of TransCode Therapeutics, Inc. - Common Stock is 1.840
When was TransCode Therapeutics, Inc. - Common Stock last traded?
The last trade of TransCode Therapeutics, Inc. - Common Stock was at 09/09/26 11:31 AM ET
What is the market capitalization of TransCode Therapeutics, Inc. - Common Stock?
The market capitalization of TransCode Therapeutics, Inc. - Common Stock is 1.53M
How many shares of TransCode Therapeutics, Inc. - Common Stock are outstanding?
TransCode Therapeutics, Inc. - Common Stock has 2M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>